118 related articles for article (PubMed ID: 35814631)
21. The Impact of Accessible Cervical Cancer Screening in Peru-The Día del Mercado Project.
Ferris DG; Shapiro J; Fowler C; Cutler C; Waller J; Guevara Condorhuaman WS
J Low Genit Tract Dis; 2015 Jul; 19(3):229-33. PubMed ID: 25943865
[TBL] [Abstract][Full Text] [Related]
22. Decline of cytology-based cervical cancer screening for COVID-19: a single-center Peruvian experience.
Rojas-Zumaran V; Walttuoni-Picón E; Campos-Siccha G; Cruz-Gonzales G; Huiza-Espinoza L; Moya-Salazar J
Medwave; 2022 Nov; 22(10):e2589. PubMed ID: 36427327
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
24. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
[TBL] [Abstract][Full Text] [Related]
25. Cervical biopsy-based comparison of a new liquid-based thin-layer preparation with conventional Pap smears.
Mattosinho de Castro Ferraz Mda G; Nicolau SM; Stávale JN; Focchi J; Castelo A; Dôres GB; Mielzynska-Lohnas I; Lorincz A; Rodrigues de Lima G
Diagn Cytopathol; 2004 Apr; 30(4):220-6. PubMed ID: 15048954
[TBL] [Abstract][Full Text] [Related]
26. A study of Pap test history and histologically determined cervical cancer in NSW women, 1997-2003.
Morrell S; Taylor R; Wain G
J Med Screen; 2005; 12(4):190-6. PubMed ID: 16417696
[TBL] [Abstract][Full Text] [Related]
27. [How does type of health insurance affect receipt of Pap testing in Peru?].
Barrionuevo-Rosas L; Palència L; Borrell C
Rev Panam Salud Publica; 2013 Dec; 34(6):393-400. PubMed ID: 24569967
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology.
Termrungruanglert W; Khemapech N; Tantitamit T; Havanond P
J Gynecol Oncol; 2019 Mar; 30(2):e17. PubMed ID: 30740950
[TBL] [Abstract][Full Text] [Related]
29. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
[TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Holmes J; Hemmett L; Garfield S
Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
[TBL] [Abstract][Full Text] [Related]
31. p16/Ki-67 dual stain, PAP cytology and HR-HPV test results prior to and 6 months after a LLETZ procedure: a prospective observational cohort study.
Packet B; Poppe W; Vanherck M; Weynand B
Arch Gynecol Obstet; 2023 Feb; 307(2):519-524. PubMed ID: 36197541
[TBL] [Abstract][Full Text] [Related]
32. An overview of environmental and toxicological aspects of aromatic hydrocarbons. III. Xylene.
Fishbein L
Sci Total Environ; 1985 May; 43(1-2):165-83. PubMed ID: 3892684
[TBL] [Abstract][Full Text] [Related]
33. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
Petry KU; Barth C; Wasem J; Neumann A
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
[TBL] [Abstract][Full Text] [Related]
34. Economic burden of Huntington's disease in Peru.
Silva-Paredes G; Urbanos-Garrido RM; Inca-Martinez M; Rabinowitz D; Cornejo-Olivas MR
BMC Health Serv Res; 2019 Dec; 19(1):1017. PubMed ID: 31888613
[TBL] [Abstract][Full Text] [Related]
35. Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical.
Mittendorf T; Nocon M; Roll S; Mühlberger N; Sroczynski G; Siebert U; Willich SN; von der Schulenburg JM
GMS Health Technol Assess; 2007 Sep; 3():Doc08. PubMed ID: 21289942
[TBL] [Abstract][Full Text] [Related]
36. Repeated Positive Cervical HPV Testing and Absent or Minor Cytology Abnormality at Pap Smear. What is the Next Step?
Caeiro V; Nunes S; Esteves B; Moutinho-Fonseca J
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1907-1912. PubMed ID: 34181350
[TBL] [Abstract][Full Text] [Related]
37. Pap tests in the diagnosis of cervical cancer: Help or hinder?
Philp L; Jembere N; Wang L; Gao J; Maguire B; Kupets R
Gynecol Oncol; 2018 Jul; 150(1):61-66. PubMed ID: 29773301
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
Vassilakos P; Poncet A; Catarino R; Viviano M; Petignat P; Combescure C
Gynecol Oncol; 2019 Apr; 153(1):92-99. PubMed ID: 30718124
[TBL] [Abstract][Full Text] [Related]
39. Liquid-based cytology: evaluation of effectiveness, cost-effectiveness, and application to present practice.
Cox JT
J Natl Compr Canc Netw; 2004 Nov; 2(6):597-611. PubMed ID: 19780303
[TBL] [Abstract][Full Text] [Related]
40. Comparison of conventional Pap smear and liquid-based cytology: A study of cervical cancer screening at a tertiary care center in Bihar.
Pankaj S; Nazneen S; Kumari S; Kumari A; Kumari A; Kumari J; Choudhary V; Kumar S
Indian J Cancer; 2018; 55(1):80-83. PubMed ID: 30147099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
